Bio Essence Corp. filed a Form 10-Q with the U.S. Securities and Exchange Commission on November 13, 2026, covering the quarterly period ended September 30, 2026, reporting a swing to profitability over the nine-month period alongside a significant acquisition of intangible assets.

Key Highlights

  • Nine-month net income: The company reported net income of $324,992 for the nine months ended September 30, 2026, compared to a net loss of $132,890 for the same period in 2025, according to the filing.
  • Third-quarter net loss: For the three months ended September 30, 2026, the company recorded a net loss of $150,458, versus net income of $12,998 in the prior-year quarter.
  • Revenue growth: Total revenues for the nine months ended September 30, 2026 were $1,548,268, up from $418,112 in the same period of 2025.
  • MediFlow AI software acquisition: The company issued 7,000,000 shares of common stock, valued at $3,500,000, to acquire the MediFlow AI software, which was recorded as an intangible asset.
  • Shares outstanding: Common shares issued and outstanding rose to 55,809,000 as of September 30, 2026, from 38,009,000 as of December 31, 2025.
  • Total assets: Total assets reached $4,000,357 as of September 30, 2026, compared to $422,474 as of December 31, 2025.
  • Stockholders' equity: Total stockholders' equity turned positive at $2,292,099 as of September 30, 2026, from a deficit of $2,072,893 at December 31, 2025.

Bio Essence Reports Revenue Surge and MediFlow AI Software Acquisition in Nine-Month 2026 Results

According to the filing, Bio Essence Corp. is a California-incorporated company primarily engaged in manufacturing and distributing health supplement products. The company's securities are not registered on a national exchange under Section 12(b); the cover page lists "N/A" for trading symbol and exchange. The filing states that 53,809,000 shares of common stock were issued and outstanding as of the latest practicable date noted on the cover, while the balance sheet reflects 55,809,000 shares as of September 30, 2026, following an additional issuance of 2,000,000 shares for equity financing during the third quarter.

The filing discloses that total revenues from OEM services for the nine months ended September 30, 2026 were $1,548,268, up from $416,896 in the year-earlier nine-month period. Cost of OEM services for the nine months was $619,493, producing a gross profit of $928,775. General and administrative expenses for the nine months totaled $592,135, the filing states. Income from operations for the nine-month period was $335,960, compared to an operating loss of $129,616 in the same period of 2025. For the third quarter alone, the company reported an operating loss of $159,125, driven in part by general and administrative expenses of $298,286.

The company disclosed a material non-cash transaction: the issuance of 7,000,000 common shares valued at $3,500,000 to acquire the MediFlow AI software, recorded as an intangible asset. As a result, intangible assets, net, increased to $3,221,438 as of September 30, 2026, from $97 at December 31, 2025. The filing also reports that the company made a $500,000 prepayment for software development during the nine-month period. Net cash used in operating activities was $721,168, while net cash provided by investing activities was $385,173, primarily reflecting repayment from a shareholder of $385,173. Cash at the end of the period was $201,511, up from zero at the start of the period.

What Was Disclosed

Bio Essence Corp. filed its 10-Q for the quarter ended September 30, 2026, disclosing nine-month net income of $324,992, a revenue increase to $1,548,268 from OEM services, the acquisition of MediFlow AI software for $3,500,000 in stock, and a shift from a stockholders' deficit to positive equity of $2,292,099.